Skip to main content
SpringerLink
Log in

Development of Novel Docetaxel Phospholipid Nanoparticles for Intravenous Administration: Quality by Design Approach

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

The objective of this study was to develop novel docetaxel phospholipid nanoparticles (NDPNs) for intravenous administration. Modified solvent diffusion-evaporation method was adopted in the NDPN preparation. Central composite design (CCD) was employed in the optimization of the critical formulation factor (drug content) and process variable (stirring rate) to obtain NDPNs with 215.53 ± 1.9-nm particle size, 0.329 ± 0.02 polydispersity index (PDI), and 75.41 ± 4.81% entrapment efficiency. The morphological examination by transmission electron microscopy revealed spherical structure composed of a drug core stabilized within the phospholipid shell. Enhanced cell uptake of coumarin-6-loaded phospholipid nanoparticles by MCF-7 cell line indicated NDPN-efficient cell uptake. In vitro hemolysis test confirmed the safety of the phospholipid nanoparticles. NDPNs exhibited increased area under the curve (AUC) and mean residence time (MRT) by 3.0- and 3.3-fold, respectively, in comparison with the existing docetaxel parenteral formulation (Taxotere®), indicating a potential for sustained action. Thus, the novel NDPNs exhibit an ability to be an intravenous docetaxel formulation with enhanced uptake, decreased toxicity, and prolonged activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  2. Mettlin C. Global breast cancer mortality statistics. CA Cancer J Clin. 1999;49(3):138–44.

    Article  CAS  PubMed  Google Scholar 

  3. Norris LB, Qureshi ZP, Bookstaver PB, Raisch DW, Sartor O, Chen H, et al. Polysorbate 80 hypersensitivity reactions: a renewed call to action. J Community Oncol. 2010;7(9):425–8.

    Article  Google Scholar 

  4. Lee SW, Yun MH, Jeong SW, In CH, Kim JY, Seo MH, et al. Development of docetaxel-loaded intravenous formulation, nanoxel-pm using polymer-based delivery system. J Control Release. 2011;155(2):262–71.

    Article  CAS  PubMed  Google Scholar 

  5. Upadhyay KK, Bhatt AN, Castro E, Mishra AK, Chuttani K, Dwarakanath BS, et al. In vitro and in vivo evaluation of docetaxel loaded biodegradable polymersomes. Macromol Biosci. 2010;10(5):503–12.

    Article  CAS  PubMed  Google Scholar 

  6. Chen ZK, Cai MX, Yang J, Lin LW, Xue ES, Huang J, et al. Chemotherapy with PLGA microspheres containing docetaxel decreases angiogenesis in human hepatoma xenograft. Med Oncol. 2012;29(1):62–9.

    Article  CAS  PubMed  Google Scholar 

  7. Esmaeili F, Dinarvand R, Ghahremani MH, Amini M, Rouhani H, Sepehri N, et al. Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies. J Pharm Sci. 2009;98(8):2718–30.

    Article  CAS  PubMed  Google Scholar 

  8. Hwang HY, Kim IS, Kwon IC, Kim YH. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Control Release. 2008;128(1):23–31.

    Article  CAS  PubMed  Google Scholar 

  9. Liu Y, Li K, Pan J, Liu B, Feng SS. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of docetaxel. Biomaterials. 2010;31(2):330–8.

    Article  CAS  PubMed  Google Scholar 

  10. Loxley A. Solid lipid nanoparticles for the delivery of pharmaceutical actives. Drug Deliv Technol 2009;9(8).

  11. Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. 2006;325(1–2):172–9.

    Article  CAS  PubMed  Google Scholar 

  12. Qiu Y, Gao Y, Hu K, Li F. Enhancement of skin permeation of docetaxel: a novel approach combining microneedle and elastic liposomes. J Control Release. 2008;129(2):144–50.

    Article  CAS  PubMed  Google Scholar 

  13. Yousefi A, Esmaeili F, Rahimian S, Atyabi F, Dinarvand R. Preparation and in vitro evaluation of a pegylated nano-liposomal formulation containing docetaxel. Sci Pharm. 2009;77:453–64.

    Article  CAS  Google Scholar 

  14. Zhai G, Wu J, Xiang G, Mao W, Yu B, Li H, et al. Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. J Nanosci Nanotechnol. 2009;9(3):2155–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Pavan KB, Subhashis D, Niranjan BM. Pharmacosomes as a novel vesicular drug delivery system. Int J Noval Trends Pharml Sci. 2013;3(3):46–52.

    Google Scholar 

  16. Semalty A, Semalty M, Rawat BS, Singh D, Rawat MS. Pharmacosomes: the lipid-based new drug delivery system. Expert Opin Drug Deliv. 2009;6(6):599–612.

    Article  CAS  PubMed  Google Scholar 

  17. Singh C, Bhatt TD, Gill MS, Suresh S. Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation. Int J Pharm. 2014;460(1–2):220–7.

    Article  CAS  PubMed  Google Scholar 

  18. Fang J, Nakamura H, Maeda H. The epr effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–51.

    Article  CAS  PubMed  Google Scholar 

  19. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11(17–18):812–8.

    Article  CAS  PubMed  Google Scholar 

  20. Singh G, Pai RS. Optimized self-nanoemulsifying drug delivery system of atazanavir with enhanced oral bioavailability: in vitro/in vivo characterization. Expert Opin Drug Deliv. 2014;11(7):1023–32.

    Article  CAS  PubMed  Google Scholar 

  21. Larabi M, Gulik A, Dedieu JP, Legrand P, Barratt G, Cheron M. New lipid formulation of amphotericin b: spectral and microscopic analysis. Biochim Biophys Acta. 2004;1664(2):172–81.

    Article  CAS  PubMed  Google Scholar 

  22. Larabi M, Yardley V, Loiseau PM, Appel M, Legrand P, Gulik A, et al. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin b. Antimicrob Agents Chemother. 2003;47(12):3774–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Li X, Wang D, Zhang J, Pan W. Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers. J Pharm Pharmacol. 2009;61(11):1485–92.

    Article  CAS  PubMed  Google Scholar 

  24. Huang XX, Zhou CL, Wang H, Chen C, Yu SQ, Xu Q, et al. Pharmacokinetics, efficacy, and safety evaluation of docetaxel/hydroxypropyl-sulfobutyl-beta-cyclodextrin inclusion complex. AAPS Pharmscitech. 2011;12(2):665–72.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Mora-Huertas CE, Fessi H, Elaissari A. Influence of process and formulation parameters on the formation of submicron particles by solvent displacement and emulsification-diffusion methods critical comparison. Adv Colloid Interf Sci. 2011;163(2):90–122.

    Article  CAS  Google Scholar 

  26. Singare DS, Marella S, Gowthamrajan K, Kulkarni GT, Vooturi R, Rao PS. Optimization of formulation and process variable of nanosuspension: an industrial perspective. Int J Pharm. 2010;402(1–2):213–20.

    Article  CAS  PubMed  Google Scholar 

  27. Papadopoulou V, Kosmidis K, Vlachou M, Macheras P. On the use of the weibull function for the discernment of drug release mechanisms. Int J Pharm. 2006;309(1–2):44–50.

    Article  CAS  PubMed  Google Scholar 

  28. Adibkia K, Siahi Shadbad MR, Nokhodchi A, Javadzedeh A, Barzegar-Jalali M, Barar J, et al. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target. 2007;15(6):407–16.

    Article  CAS  PubMed  Google Scholar 

  29. Rivolta I, Panariti A, Lettiero B, Sesana S, Gasco P, Gasco MR, et al. Cellular uptake of coumarin-6 as a model drug loaded In solid lipid nanoparticles. J Physiol Pharmacol. 2011;62(1):45–53.

    CAS  PubMed  Google Scholar 

  30. Gao H, Yang Z, Zhang S, Cao S, Shen S, Pang Z, et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep. 2013;3:1–8.

    Google Scholar 

  31. Fang G, Tang B, Liu Z, Gou J, Zhang Y, Xu H, et al. Novel hydrophobin-coated docetaxel nanoparticles for intravenous delivery: in vitro characteristics and in vivo performance. Eur J Pharm Sci. 2014;60:1–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to express their gratitude to the Mr. Ashok K. Datusalia, Piyush Dave, Prashant Gupta (Department of Pharmacology and Toxicology), and Charan Singh (Department of Pharmaceutical Technology) for their valuable support in conducting the animal studies. We thank Lipoid (GmbH, Germany) for providing gift samples of phospholipids.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Technology (Formulation), National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, SAS Nagar (Mohali), Punjab, 160062, India

    Dharmendra K. Yadav, Harish Pawar, Shrikant Wankhade & Sarasija Suresh

Authors
  1. Dharmendra K. Yadav
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harish Pawar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shrikant Wankhade
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sarasija Suresh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarasija Suresh.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yadav, D.K., Pawar, H., Wankhade, S. et al. Development of Novel Docetaxel Phospholipid Nanoparticles for Intravenous Administration: Quality by Design Approach. AAPS PharmSciTech 16, 855–864 (2015). https://doi.org/10.1208/s12249-014-0274-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-014-0274-9

KEY WORDS

Search

Navigation